According to a recent LinkedIn post from F-Prime, the firm is among a syndicate of investors backing Immutrin’s £65 million ($87 million) Series A financing. The post highlights that Immutrin is developing next‑generation antibody therapies targeting ATTR amyloidosis, with a lead asset focused on ATTR cardiomyopathy, a progressive and potentially fatal heart condition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Immutrin’s approach aims to harness the body’s immune system to actively remove amyloid deposits from affected tissues, addressing a significant unmet medical need in cardiology. For investors, F-Prime’s participation in this sizable early‑stage round reinforces its exposure to high‑risk, high‑reward biotech innovation and could enhance its positioning in the competitive cardiovascular and rare disease therapeutics space.
If Immutrin’s platform demonstrates clinical efficacy and safety, the investment could translate into meaningful value creation over the medium to long term, though development and regulatory risks remain substantial. The presence of multiple specialist life sciences investors, as cited in the post, may also indicate strong sector confidence in the company’s scientific approach and the commercial potential of disease‑modifying therapies for ATTR amyloidosis.